← Back

Wire · opportunities

Venus Medtech (Hangzhou) Inc. Reports 76.9% Had None/Trace TR at 3 Years

Published

22 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Europe

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Venus Medtech reported that 76.9% of patients in its TARGET Study had none or trace tricuspid regurgitation three years after implantation, with improved safety outcomes for its enhanced valve system and plans to seek CE Mark approval for EU commercialization by mid-2027.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now plan to enter the EU market with a valve system backed by strong three-year safety data and improved bleeding outcomes. The CE Mark approval process creates a clear timeline for expanding your clinical and commercial reach by mid-2027.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Medtechvalve-systemclinical-studymedtech-eu-approvalsafety-improvementtricuspid-regurgitation